Enveric Biosciences, Inc. carries no debt; cash flow comfortably covers obligations.

Enveric Biosciences, Inc.'s free cash flow has decreased 5.38% from $-7.73M last year to $-8.14M, signaling decreasing performance

Enveric Biosciences, Inc.'s debt to equity ratio is 0.00, which means that the company's assets are healthy financed, signaling financial stability.

Enveric Biosciences, Inc. has insufficient data to evaluate this check.

Enveric Biosciences, Inc. has a net cash position, so leverage is healthy.

Enveric Biosciences, Inc. carries no debt; interest obligations are fully covered.

Enveric Biosciences, Inc. has insufficient data to evaluate this check.

Enveric Biosciences, Inc.'s short-term assets of $4.94M exceed its short-term liabilities of $918.40K

Enveric Biosciences, Inc.'s return on assets of 0.00% is lower than the 5.00% threshold, indicating inefficient asset utilization

Enveric Biosciences, Inc.'s return on equity of -220.99%, is lower than 15.00%, indicating bad performance

Enveric Biosciences, Inc.'s operating cash flow is lower than its net income, indicating that earnings may not be fully backed by cash generation

Enveric Biosciences, Inc. had positive net income in only 0 out of 5 years, indicating unstable earnings

Enveric Biosciences, Inc. has negative free cash flow, indicating the company is burning cash rather than generating it

Enveric Biosciences, Inc. has negative free cash flow, indicating cash burn

Enveric Biosciences, Inc.'s yearly earnings has decreased 26.70% since last year from $-9.57M to $-12.13M, signaling decreasing performance

Enveric Biosciences, Inc.'s yearly revenue has increased 0.00% since last year from $0.00 to $0.00, signaling increasing performance

ROIC -162.43% (Source: FMP key-metrics). Below the 5% partial-credit threshold. Score: 0 of 2. The 5% and 10% cutoffs anchor to typical US weighted-average cost of capital. Below 5% indicates the company is not generating returns above its likely cost of capital under this definition of invested capital. Invested capital here includes equity, non-current liabilities (pension obligations, deferred taxes, lease obligations), and short-term debt. Cash is not subtracted. Companies with substantial float, lease portfolios, or cash holdings will score lower under this definition than under narrower operating-capital definitions. See methodology.

Enveric Biosciences, Inc. has insufficient revenue history to calculate 3-year revenue CAGR.

Enveric Biosciences, Inc. had revenue growth in 5 out of 5 years, indicating consistent revenue performance

Enveric Biosciences, Inc. had positive ROE in only 0 out of 5 years, indicating inconsistent returns on equity

Enveric Biosciences, Inc. has insufficient data to evaluate this check.

Enveric Biosciences, Inc. has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails

Enveric Biosciences, Inc. is overvalued relative to its fair value price of 0.00 based on EBITDA multiple model

Enveric Biosciences, Inc. has negative or missing EBITDA, making EV/EBITDA ratio unreliable

Enveric Biosciences, Inc. has insufficient data to evaluate this check.

Enveric Biosciences, Inc. has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails

Enveric Biosciences, Inc. has a price-to-book ratio of 0.46x, which is below the 5.00x threshold, indicating reasonable valuation relative to its book value

Enveric Biosciences, Inc. has a price-to-sales ratio of 999.00x, which exceeds the 8.00x threshold, indicating the stock may be overvalued relative to its revenue